SCHEMBL1789847

SCHEMBL1789847

NC(=O)c1ccccc1-c1cccc(O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.67
PARP1 P09874 4/20 0.51
IKBKB O14920 2/20 0.49
CHEK1 O14757 1/20 0.49
AKR1C3 P42330 2/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
GRK2 P25098 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10908563 0.89 BCAT2 (0.77) BCAT2PARP1IKBKBCHEK1KDM4E
SCHEMBL3624407 0.85 BCAT2 (0.49) BCAT2PARP1IKBKBCHEK1AKR1C3
SCHEMBL16149659 0.85 BCAT2 (0.91) BCAT2PARP1IKBKBCHEK1KDM4E
SCHEMBL456065 0.84 HNF4A (0.59) BCAT2AKR1C3ALDH1A1MAPTHSD17B10
SCHEMBL28353842 0.84 BCAT2 (0.75) BCAT2PARP1IKBKBCHEK1KEAP1
SCHEMBL1456885 0.82 BCAT2 (0.67) BCAT2PARP1IKBKBCHEK1KDM4E
SCHEMBL28096188 0.82 BCAT2 (0.67) BCAT2PARP1CHEK1MAPTTSHR
SCHEMBL12505389 0.81 TSHR (0.46) BCAT2PARP1IKBKBAKR1C3KDM4E
SCHEMBL3632646 0.81 BCAT2 (0.65) BCAT2PARP1CHEK1MAPTKEAP1
SCHEMBL3632126 0.81 BCAT2 (0.65) BCAT2PARP1IKBKBCHEK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633175-B2 Compounds as antagonists or inverse agonists at opioid receptors GLAXOSMITHKLINE LLC (US) 2014-01-21 US disclosed
US-20110124559-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2011-05-26 US disclosed
EP-1633715-A1 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS Pfizer Limited (GB) 2006-03-15 EP disclosed
WO-2004108676-A1 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS PFIZER LIMITED (GB) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124559-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 BCAT2 2529/4885PARP1 4618/4885IKBKB 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.